Genmab A/S (GMAB) Financials
GMAB Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 12.4 billion | 6.7 billion |
| Dec. 31, 2025 | 12.8 billion | 7.0 billion |
| Sept. 30, 2025 | 7.0 billion | 1.3 billion |
| June 30, 2025 | 41.0 billion | 1.2 billion |
GMAB Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | -2.0 million | ? |
| Dec. 31, 2025 | 287.4 million | 36.0 million |
| Sept. 30, 2025 | 534.0 million | 34.0 million |
| June 30, 2025 | 329.5 million | 209.1 million |
GMAB Net Income
Graph available only for paid members. Upgrade to see it.
| Date | Net Income |
|---|---|
| March 31, 2026 | 53.2 million |
| Dec. 31, 2025 | 30.9 million |
| Sept. 30, 2025 | 482.0 million |
| June 30, 2025 | 2.7 billion |
GMAB Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 1.5 billion | 4.9 billion | 125.0 million |
| Dec. 31, 2025 | 1.7 billion | 5.0 billion | 151.7 million |
| Sept. 30, 2025 | 3.4 billion | - | 142.0 million |
| June 30, 2025 | 18.4 billion | - | 148.2 million |
GMAB Shares Outstanding
GMAB Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | 5.0 million | 441.6 million | 166.6 million | - |
| Dec. 31, 2025 | 13.0 million | 524.4 million | 207.4 million | - |
| Sept. 30, 2025 | 2.0 million | 357.0 million | 148.0 million | - |
| June 30, 2025 | 10.0 million | 364.4 million | 144.2 million | - |
GMAB Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | 899.3 million | 65.2 million |
| Dec. 31, 2025 | 1.1 billion | 80.8 million |
| Sept. 30, 2025 | 1.0 billion | 58.0 million |
| June 30, 2025 | 926.1 million | 361.2 million |
GMAB
Price: $25.15
52 week price:
Earnings Per Share: 1.31 USD
P/E Ratio: 20.27
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: Denmark
Volume: 221594
Market Capitalization: 15.4 billion